ID: ALA370772

Max Phase: Preclinical

Molecular Formula: C21H16ClNO4S

Molecular Weight: 413.88

Molecule Type: Small molecule

Representations

Canonical SMILES:  COCc1c(Cl)sc2nc(O)c(-c3cccc(Oc4ccccc4)c3)c(O)c12

Standard InChI:  InChI=1S/C21H16ClNO4S/c1-26-11-15-17-18(24)16(20(25)23-21(17)28-19(15)22)12-6-5-9-14(10-12)27-13-7-3-2-4-8-13/h2-10H,11H2,1H3,(H2,23,24,25)

Standard InChI Key:  RFMZUQDRDGMRMO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 413.88

Molecular Weight (Monoisotopic): 413.0489

AlogP: 5.97

#Rotatable Bonds: 5

Polar Surface Area: 71.81

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.27

CX Basic pKa:

CX LogP: 5.78

CX LogD: 5.77

Aromatic Rings: 4

Heavy Atoms: 28

QED Weighted: 0.42

Np Likeness Score: -0.51

References

1. Buchstaller HP, Siebert CD, Steinmetz R, Frank I, Berger ML, Gottschlich R, Leibrock J, Krug M, Steinhilber D, Noe CR..  (2006)  Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor.,  49  (3): [PMID:16451052] [10.1021/jm0503493]

Source

Source(1):

• Scientific Literature